TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7970790
Drug: Skin end‐point
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin end‐point titration based immunotherapy
Study: 7970790
Drug: Prick testing
Normalized name: prickly pear fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prick testing based immunotherapy
Study: 7970790
Drug: Scratch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scratch testing based immunotherapy
Study: 27149496
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BFT) during the temporary stoma period
Study: 24275838
Drug: Valsartan-amlodipine (80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan-amlodipine (80/5 mg, then 160/10 mg)
Study: 24275838
Drug: Atenolol-amlodipine (50/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol-amlodipine (50/5 mg, then 100/10 mg)
Study: 12133124
Drug: Gradual benzodiazepine
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual benzodiazepine taper combined with cognitive-behavioural therapy
Study: 12133124
Drug: Standard withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard withdrawal treatment
Study: 10224354
Drug: rhuMAb‐E25 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuMAb‐E25 (humanized monoclonal antibody against IgE)
Study: 1691367
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg felodipine extended-release (ER) tablets
Study: 523172
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg FK (synthetic enkephalin analogue) intramuscularly
Study: 523172
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg FK intramuscularly
Study: 523172
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg FK intramuscularly
Study: 523172
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg betazole (placebo)
Study: 27794193
Drug: Water sweetened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water sweetened with saccharin (5 mg/kg body weight)
Study: 15598481
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 135 mg (<or=5 doses/d)
Study: 15598481
Drug: Loperamide 4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 4 mg (loading dose) followed by 2 mg (<or=8 mg/d) after each loose stool
Study: 11386493
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and self-help manual
Study: 8820889
Drug: Long, continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long, continuous contractions (CC)
Study: 1317343
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg immune serum globulin
Study: 1317343
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg immune serum globulin
Study: 1317343
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (1 microgram/dose)
Study: 1317343
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (0.5 micrograms/dose)
Study: 1317343
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (0.25 micrograms/dose)
Study: 29465549
Drug: Metabolic rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic rehabilitation program composed of aerobic and resisted exercises, performed for 12 weeks, in 3 weekly meetings of 60 minutes each.
Study: 26982602
Drug: Pregabalin-Duloxetine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin-Duloxetine Combination
Study: 22865033
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline alternating with 5% dextrose at rate of 175 ml/h
Study: 7846539
Drug: daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral etoposide/ifosfamide/cisplatin
Study: 30580454
Drug: saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin (5 mg/day)
Study: 29083936
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (50 mg losartan/12.5 mg HCTZ)
Study: 29083936
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (100 mg losartan)
Study: 24494695
Drug: Prior mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior mental health specialty treatment
Study: 16317534
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/daily) for a maximum of 2 weeks
Study: 16317534
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (diclofenac 100 mg/daily plus aescin 80 mg/daily)
Study: 12883407
Drug: Propofol (target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target-controlled infusion at concentrations of 2, 4, or 6 microg/ml)
Study: 12883407
Drug: Remifentanil (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (increasing concentrations from 0 to 7 ng/ml)
Study: 8914115
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patches (placebo, low 7 mg/day, medium 14 mg/day, high 21 mg/day)
Study: 8914115
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patches (all doses)
Study: 1711261
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 500 ml hydroxyethylstarch 6% 0.62
Study: 1711261
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 5000 IE unfractionated heparin
Study: 6406947
Drug: Flutonidin (F)
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutonidin (F) 2 mg/day
Study: 6406947
Drug: Clonidine (C)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (C) 0.3 mg/day
Study: 30629889
Drug: Metformin (completers)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (completers)
Study: 30629889
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance group
Study: 29191561
Drug: Nexvax2 starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nexvax2 starting dose of 3μg in cohort 1
Study: 29191561
Drug: Nexvax2 starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nexvax2 starting dose of 30μg in cohort 1
Study: 29191561
Drug: Nexvax2 starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nexvax2 starting dose of 3μg in cohort 2
Study: 29191561
Drug: Nexvax2 starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nexvax2 starting dose of 3μg in cohort 3
Study: 29191561
Drug: Nexvax2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexvax2 treatment at dose levels from 150μg to 900μg
Study: 29191561
Drug: Nexvax2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexvax2 treatment
Study: 21903027
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus omega-3
Study: 18670195
Drug: Formulation 13
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 13
Study: 18670195
Drug: Formulation 14
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 14
Study: 18670195
Drug: Formulation 17
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 17
Study: 15154363
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid addition with standard therapy
Study: 7516019
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg i.v. infusion)
Study: 7516019
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg oral daily for 5 days)
Study: 29554385
Drug: Intravitreous aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous aflibercept injection (IAI) with a fixed bimonthly regimen for the first 2 years, followed by routine clinical practice regimen in the third year.
Study: 22999261
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg twice daily; PO)
Study: 22999261
Drug: Metformin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (750 mg twice daily; PO)
Study: 21371770
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lipoic acid (LA)
Study: 21371770
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg α-tocopherol
Study: 21371770
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg α-tocopherol + 600 mg lipoic acid (LA)
Study: 12057717
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) at a dose of 1.8 g/day orally for 5-6 weeks; 3 g/day for massively obese subjects
Study: 7175716
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g probenecid
Study: 7175716
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g probenecid
Study: 29449764
Drug: Neuroplasticity explanation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroplasticity explanation with manual therapy
Study: 29449764
Drug: Mechanical explanation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical explanation with manual therapy
Study: 26374743
Drug: N-Acetyl Cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetyl Cysteine (NAC) 3 g/day (1.5 g twice daily)
Study: 17631083
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of digoxin therapy
Study: 14716705
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg b.d.)
Study: 14716705
Drug: Milnacipran (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (100 mg per day for 7 days)
Study: 12803656
Drug: Current treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatments for MG
Study: 9845709
Drug: Standard triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone)
Study: 7852209
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) therapy
Study: 3188866
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical therapy combined with 2 hours of passive knee motion twice daily from 2-12 days after total knee arthroplasty
Study: 3188866
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical therapy only
Study: 26715040
Drug: Augmented cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented cognitive behavioural therapy (augmented CBT)
Study: 19192463
Drug: Continuation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation and maintenance antidepressant medication
Study: 15215815
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/d for 1 week) plus Clopidogrel (75 mg/d for 3 weeks)
Study: 15215815
Drug: Warfarin (international
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (international normalized ratio, 2 to 3 for 3 weeks)
Study: 8398293
Drug: Clodronate (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1.6 g daily)
Study: 3598328
Drug: Intravenous alpha-2
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha-2 interferon (50 X 10(6) U/m2) on 5 consecutive days every 4 weeks
Study: 3598328
Drug: Subcutaneous alpha-2
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous alpha-2 interferon (20 X 10(6) U/m2) three times per week
Study: 3598328
Drug: Intravenous alpha-2
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha-2 interferon (20 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Study: 3598328
Drug: Subcutaneous alpha-2
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous alpha-2 interferon (5 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Study: 28606437
Drug: Price-aware group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Price-aware group (surgeons received implant prices)
Study: 28606437
Drug: Price-naïve group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Price-naïve group (surgeons did not receive implant prices)
Study: 23419552
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (iCBT) programme
Study: 16359965
Drug: Luteinizing hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone (LH)
Study: 16359965
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of MIS with reproductive hormones and insulin
Study: 9496522
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously 30 min before and 8 and 16 hours after ERCP
Study: 31487271
Drug: Linked dual-class
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linked dual-class drug resistance mutations (DRMs) present before ART initiation
Study: 31487271
Drug: Linked single-class
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linked single-class drug resistance mutations (DRMs) present before ART initiation
Study: 31487271
Drug: Combination ART
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ART with 3 drugs (nevirapine/tenofovir/emtricitabine)
Study: 28991344
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic treatment (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and timolol maleate 0.5% gel)
Study: 28991344
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment only (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and simple eye ointment)
Study: 27306492
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral chlorzoxazone
Study: 22016348
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 17)
Study: 19535243
Drug: CEF (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (adjuvant epirubicin-based chemotherapy)
Study: 19535243
Drug: CMF (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (adjuvant methotrexate-based chemotherapy)
Study: 19535243
Drug: TIMP-1 status
Normalized name: chlorcyclizine hydrochloride 2.5 MG/ML / codeine phosphate 1.8 MG/ML / pseudoephedrine hydrochloride 6 MG/ML [Statuss Green Reformulated Jan 2012]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMP-1 status (positive or negative) versus treatment (CMF or CEF) interaction
Study: 15293606
Drug: One-stage LAUP
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage LAUP treatment
Study: 15293606
Drug: Placebo (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (simulated snore surgery followed by an oral placebo)
Study: 11887802
Drug: Bicarbonate/lactate-based solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate-based solution (B/L)
Study: 11887802
Drug: Lactate-based control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-based control solution (C)
Study: 9512112
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg + Amoxicillin 1.5 g (LA group; 21 patients)
Study: 9512112
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg + Amoxicillin 1.5 g + Rebamipide 300 mg (LAM group; 36 patients)
Study: 7802317
Drug: Acelysin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acelysin infusion
Study: 24423909
Drug: Nutritional liquid
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional liquid supplement designed for diabetes mellitus
Study: 18715244
Drug: Intravaginal dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal dinoprostone (2 mg once every 6 hours)
Study: 16907931
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg day‐1; n=13)
Study: 16907931
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg day‐1; n=13)
Study: 16907931
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (quinapril + atorvastatin)
Study: 2088770
Drug: IdB 1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdB 1016 (360 mg silybin equivalent)
Study: 2088770
Drug: Silymarin (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (360 mg silybin equivalent)
Study: 2088770
Drug: IdB 1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdB 1016 (120 mg b.i.d. for 8 days)
Study: 276348
Drug: Tumour cell
Normalized name: Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour cell vaccine
Study: 28541810
Drug: Carbohydrate-, glutamine-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-, glutamine-, and antioxidant-enriched oral nutrition supplement (S)
Study: 27295381
Drug: Topical bFGF
Normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bFGF application
Study: 23537456
Drug: Pharmacotherapy follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy follow-up (PF) via clinical pharmacy intervention at monthly visits over a 3-month follow-up period
Study: 23537456
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Control Group)
Study: 20613498
Drug: Routine stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine stenting with drug-eluting stents (DES) in both branches (group MV plus SB)
Study: 19010201
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 10 ppm from the start of LT until 48 hours afterward
Study: 19010201
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iNO treatment)
Study: 14672246
Drug: Nutritionally-sourced TRP
Normalized name: Trp
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutritionally-sourced TRP (1.8 g daily)
Study: 11013378
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (50-200 mg per day)
Study: 8345068
Drug: Follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle-stimulating hormone (FSH) (Metrodin)
Study: 20462632
Drug: Active art
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active art therapy
Study: 18337480
Drug: High-dose CVVHDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CVVHDF (35 ml/kg per h)
Study: 18337480
Drug: Standard-dose CVVHDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CVVHDF (20 ml/kg per h)
Study: 15968293
Drug: Anti-CD25 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD25 monoclonal antibody (basiliximab)
Study: 11211367
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy and behavioral treatment
Study: 11211367
Drug: Titration-determined dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration-determined dose
Study: 9723557
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous pump spray (Rhinocort Aqua) 32, 64, 128, or 256 microg once daily for 6 weeks
Study: 9723557
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous pump spray (256 microg)
Study: 9723557
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous pump spray (any active treatment group)
Study: 9723557
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous pump spray